NCT07831122
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07831122
Title Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Acronym MAPLE
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Canadian Myeloma Research Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.